Medicare kicks off temporary, discounted obesity-drug coverage for eligible seniors
Medicare will launch the temporary GLP-1 Bridge program on July 1, offering eligible Part D enrollees access to weight-loss drugs (Wegovy, Zepbound, Foundayo) for about $50 a month, subject to BMI and health criteria. The 18-month pilot tests new coverage ahead of a potential Balance model in 2028; costs to Medicare are uncertain and depend on enrollment. While many seniors could benefit, eligibility gaps remain, and questions linger about post-Bridge access and insurer participation. Drugs can be obtained via pharmacies or LillyDirect, and manufacturers say supply is sufficient. The program aims to treat obesity like other diseases and reduce related health risks, though long-term savings are debated.
- Medicare will start covering weight-loss drugs on July 1 for the first time. Here’s what you need to know CNN
- Medicare is about to cover GLP-1 drugs for weight loss. Here’s what to know. The Washington Post
- Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet CNBC
- Medicare to Cover GLP-1 Weight-Loss Drugs For $50 a Month: See If You’re Eligible TODAY.com
- Medicare will help pay for weight-loss drugs Wegovy, Zepbound. What to know USA Today
Want the full story? Read the original reporting
Read on CNN